Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and …
A Russo, T Franchina, G Ricciardi, A Battaglia… - International Journal of …, 2019 - mdpi.com
… NSCLC, but its role in patients harboring EGFR mutations … of uncommon mutations to
currently available EGFR TKIs is … patients harboring uncommon EGFR mutations with currently …
currently available EGFR TKIs is … patients harboring uncommon EGFR mutations with currently …
[HTML][HTML] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
… In conclusion, uncommon EGFR mutations may be associated with a poor outcome and the
… in cases of double uncommon mutations and such patients should be treated accordingly. …
… in cases of double uncommon mutations and such patients should be treated accordingly. …
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …
… Our findings suggested that only patients with rare EGFR mutations could receive platinum-…
and short PFS in response to EGFR-TKIs. Consequently, EGFR-TKIs could be reserved as a …
and short PFS in response to EGFR-TKIs. Consequently, EGFR-TKIs could be reserved as a …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
… against major uncommon EGFR mutations including compound mutations, but … uncommon
EGFR mutations. Moving forward, it will be important to include uncommon EGFR mutations …
EGFR mutations. Moving forward, it will be important to include uncommon EGFR mutations …
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
J Xu, B Jin, T Chu, X Dong, H Yang, Y Zhang, D Wu… - Lung cancer, 2016 - Elsevier
… uncommon EGFR mutations and their sensitivity to EGFR … patients harboring uncommon
EGFR mutations with treatment … 95 Patients who received therapy that consisted of EGFR TKIs …
EGFR mutations with treatment … 95 Patients who received therapy that consisted of EGFR TKIs …
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
… Here, we describe a case of a patient with advanced NSCLC with an uncommon EGFR
mutation who was treated with pulse dose weekly afatinib with durable and tolerable disease …
mutation who was treated with pulse dose weekly afatinib with durable and tolerable disease …
[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
… receptor (EGFR) tyrosine kinase inhibitors (… mutations in the EGFR. However, limited data
are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations…
are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations…
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and …
E Massarelli, FM Johnson, HS Erickson, II Wistuba… - Lung Cancer, 2013 - Elsevier
… clinical reference of the sensitivity of uncommon EGFR mutations to EGFR-TKIs, we have …
deal with uncommon mutations. In this review, we systematically categorized these mutations, …
deal with uncommon mutations. In this review, we systematically categorized these mutations, …
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review
… uncommon EGFR mutations, treated in our Institution with first or second generation TKIs. …
only), this review underlines that uncommon EGFR mutations are an heterogeneous group of …
only), this review underlines that uncommon EGFR mutations are an heterogeneous group of …
Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer
… uncommon EGFR mutations, such as their association with the effectiveness of EGFR tyrosine
kinase inhibitors (… of these uncommon EGFR mutations of unknown clinical significance. …
kinase inhibitors (… of these uncommon EGFR mutations of unknown clinical significance. …
相关搜索
- cell lung cancer uncommon egfr mutations
- growth factor tyrosine kinase inhibitors
- patients with uncommon egfr mutations
- literature review tyrosine kinase inhibitors
- clinical outcomes uncommon egfr mutations
- lung adenocarcinoma tyrosine kinase inhibitors
- egfr tyrosine kinase inhibitors resistance mutations
- complex egfr mutations tyrosine kinase inhibitors
- egfr tyrosine kinase inhibitors mutation types
- role of egfr tyrosine kinase inhibitors
- somatic mutations tyrosine kinase inhibitor response
- tyrosine kinase inhibitor activity
- common and rare egfr mutations
- nsclc with uncommon egfr mutations
- efficacy of tyrosine kinase inhibitor
- rare egfr mutations distinct epidemiology